Lyell Immunopharma Inc
LYEL
Company Profile
Business description
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
Contact
201 Haskins Way
South San FranciscoCA94080
USAT: +1 650 695-0677
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
300
Stocks News & Analysis
stocks
10 best global blue-chip stocks to buy for the long term
The stocks of these high-quality companies with large market capitalizations look undervalued today.
stocks
3 overvalued ASX shares going into earnings
Prices of these shares exceed our Fair Value Estimate by more than double.
stocks
The long-term case for compounders
Compounders tend to deliver steadier, more durable profit growth across full cycles, making them better suited for long-term investors.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,068.80 | 42.20 | -0.46% |
| CAC 40 | 8,196.78 | 70.25 | 0.86% |
| DAX 40 | 24,757.71 | 218.90 | 0.89% |
| Dow JONES (US) | 48,892.47 | 179.09 | -0.36% |
| FTSE 100 | 10,317.65 | 94.11 | 0.92% |
| HKSE | 26,775.57 | 611.54 | -2.23% |
| NASDAQ | 23,461.82 | 223.30 | -0.94% |
| Nikkei 225 | 52,655.18 | 667.67 | -1.25% |
| NZX 50 Index | 13,412.44 | 10.74 | -0.08% |
| S&P 500 | 6,939.03 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,778.60 | 42.50 | -0.48% |
| SSE Composite Index | 4,015.75 | 102.20 | -2.48% |